According to the Congressional Budget Office (CBO), enacting the bill would increase direct spending by about $18.7 billion and increase direct revenues by $26.2 billion, resulting in a net decrease in the deficit of $7.6 billion by 2029.
The Congressional Budget Office (CBO) has released its score of the Senate Committee on Health, Education, Labor, and Pensions’ proposed bill, S.1895, the Lower Health Care Costs Act. According to the CBO, enacting the bill would increase direct spending by about $18.7 billion and increase direct revenues by $26.2 billion, resulting in a net decrease in the deficit of $7.6 billion by 2029.
The proposed legislation comprises 5 elements: ending surprise medical bills, reducing the prices of prescription drugs, improving transparency in health care, improving public health, and improving the exchange of health information.
Among those sections, elements aimed at reducing drug prices would be responsible for a substantial share of the savings; the CBO says that these provisions would result in a net decrease in the deficit of $4.6 billion over the coming decade.
Key to reducing drug prices are several of the bill’s provisions that apply to generics and biosimilars. According to the CBO, some of these elements of the bill would allow generics and biosimilars to reach the market sooner, leading to a decline in federal spending on prescription drugs and subsidies for health insurance.
Provisions in this portion of the bill would allow the FDA to:
The CBO states that the section of the bill providing the right to sue over sample availability and removal of the requirement to share a risk management system would, on its own, account for more than $3.7 billion in savings over 10 years. This substantial reduction in the deficit would result, in part, from the ability of generics and biosimilars to reach the market 1 to 2 years earlier, on average.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.